

Elgene Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1468871/publications.pdf>

Version: 2024-02-01

106
papers

9,371
citations

76326

40
h-index

42399

92
g-index

122
all docs

122
docs citations

122
times ranked

17035
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. <i>Nature Medicine</i> , 2009, 15, 907-913.	30.7	1,261
2	EMT, cell plasticity and metastasis. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 645-654.	5.9	672
3	XBP1 promotes triple-negative breast cancer by controlling the HIF1 α pathway. <i>Nature</i> , 2014, 508, 103-107.	27.8	663
4	A single-cell and spatially resolved atlas of human breast cancers. <i>Nature Genetics</i> , 2021, 53, 1334-1347.	21.4	535
5	ROAST: rotation gene set tests for complex microarray experiments. <i>Bioinformatics</i> , 2010, 26, 2176-2182.	4.1	463
6	Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. <i>Breast Cancer Research</i> , 2010, 12, R21.	5.0	354
7	CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. <i>Cell</i> , 2015, 163, 174-186.	28.9	346
8	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1385-1393.	10.7	342
9	Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer. <i>Cancer Cell</i> , 2011, 20, 119-131.	16.8	340
10	Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. <i>Nature Communications</i> , 2018, 9, 2897.	12.8	293
11	Protein Kinase C β Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells. <i>Cancer Cell</i> , 2013, 24, 347-364.	16.8	277
12	Clinical Overview of MDM2/X-Targeted Therapies. <i>Frontiers in Oncology</i> , 2016, 6, 7.	2.8	266
13	Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. <i>EMBO Journal</i> , 2020, 39, e104063.	7.8	224
14	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2016, 17, 2367-2381.	6.4	215
15	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2766-2771.	7.1	173
16	Targeting CDK2 in cancer: challenges and opportunities for therapy. <i>Drug Discovery Today</i> , 2020, 25, 406-413.	6.4	140
17	A laminin 511 matrix is regulated by TAZ and functions as the ligand for the β 1 integrin to sustain breast cancer stem cells. <i>Genes and Development</i> , 2015, 29, 1-6.	5.9	131
18	PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair. <i>Cancer Discovery</i> , 2014, 4, 1430-1447.	9.4	125

#	ARTICLE	IF	CITATIONS
19	IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. <i>Nature Communications</i> , 2015, 6, 8746.	12.8	125
20	The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. <i>Nature Medicine</i> , 2021, 27, 310-320.	30.7	122
21	The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor. <i>Cancer Cell</i> , 2013, 24, 365-378.	16.8	120
22	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. <i>Nature Medicine</i> , 2018, 24, 463-473.	30.7	120
23	MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. <i>ELife</i> , 2014, 3, e01763.	6.0	104
24	A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. <i>Nature Communications</i> , 2018, 9, 2311.	12.8	104
25	Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, R15-R30.	3.1	96
26	Targeting the Androgen Receptor in Breast Cancer. <i>Current Oncology Reports</i> , 2015, 17, 4.	4.0	86
27	Amplitude modulation of androgen signaling by c-MYC. <i>Genes and Development</i> , 2013, 27, 734-748.	5.9	78
28	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. <i>Cancer Cell</i> , 2014, 26, 222-234.	16.8	71
29	The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy Cytopathology. <i>Acta Cytologica</i> , 2019, 63, 257-273.	1.3	71
30	The natural history of hormone receptor-positive breast cancer. <i>Oncology</i> , 2012, 26, 688-94, 696.	0.5	70
31	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R123-R144.	3.1	64
32	Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. <i>Cancer Immunology Research</i> , 2017, 5, 871-884.	3.4	63
33	Breast Cancer in Adolescents and Young Adults: A Review With a Focus on Biology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1060-1069.	4.9	59
34	Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. <i>Cell Reports</i> , 2017, 18, 2359-2372.	6.4	59
35	MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. <i>Cancer Discovery</i> , 2016, 6, 45-58.	9.4	57
36	IKK Kinase μ Phosphorylates TRAF2 To Promote Mammary Epithelial Cell Transformation. <i>Molecular and Cellular Biology</i> , 2012, 32, 4756-4768.	2.3	56

#	ARTICLE	IF	CITATIONS
37	PDEF Promotes Luminal Differentiation and Acts as a Survival Factor for ER-Positive Breast Cancer Cells. <i>Cancer Cell</i> , 2013, 23, 753-767.	16.8	56
38	The role of MDM2 and MDM4 in breast cancer development and prevention. <i>Journal of Molecular Cell Biology</i> , 2017, 9, 53-61.	3.3	56
39	Estrogen receptor signaling is reprogrammed during breast tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11437-11443.	7.1	55
40	IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG. <i>Oncogene</i> , 2016, 35, 1111-1121.	5.9	51
41	DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity. <i>Cell Reports</i> , 2021, 36, 109722.	6.4	39
42	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. <i>Nature Communications</i> , 2021, 12, 5112.	12.8	38
43	MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 87.	5.0	37
44	Pushing estrogen receptor around in breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T227-T241.	3.1	35
45	Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 43.	5.0	33
46	The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 271-278.	2.5	31
47	A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1023-1023.	1.6	29
48	Non-canonical AR activity facilitates endocrine resistance in breast cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 251-264.	3.1	29
49	Renewed interest in the progesterone receptor in breast cancer. <i>British Journal of Cancer</i> , 2016, 115, 909-911.	6.4	28
50	Secreted Tumor Antigens “ Immune Biomarkers for Diagnosis and Therapy. <i>Proteomics</i> , 2017, 17, 1600442.	2.2	27
51	Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1020.	1.6	27
52	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. <i>Genome Medicine</i> , 2021, 13, 81.	8.2	25
53	Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. <i>Clinical Endocrinology</i> , 2018, 89, 280-296.	2.4	24
54	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 667.	4.1	19

#	ARTICLE	IF	CITATIONS
55	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	2.4	18
56	Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. <i>Endocrine-Related Cancer</i> , 2020, 27, R93-R112.	3.1	16
57	Epigenetic Therapies and Biomarkers in Breast Cancer. <i>Cancers</i> , 2022, 14, 474.	3.7	16
58	Adjuvant chemotherapy in luminal breast cancers. <i>Breast</i> , 2011, 20, S128-S131.	2.2	15
59	A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1021-1021.	1.6	15
60	Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens. <i>Melanoma Research</i> , 2006, 16, 347-355.	1.2	14
61	Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models. <i>Breast Cancer Research</i> , 2021, 23, 82.	5.0	14
62	Subsite-Specific Colorectal Cancer in Diabetic and Nondiabetic Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1579-1582.	2.5	13
63	Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy. <i>Current Breast Cancer Reports</i> , 2014, 6, 71-78.	1.0	13
64	Elucidating the role of androgen receptor in breast cancer. <i>Clinical Investigation</i> , 2012, 2, 1003-1011.	0.0	11
65	Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary. <i>Medical Journal of Australia</i> , 2019, 211, 224-229.	1.7	11
66	CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-14.	1.1	11
67	Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes. <i>Cancers</i> , 2019, 11, 682.	3.7	10
68	Testosterone therapy considerations in oestrogen, progesterone and androgen receptor-positive breast cancer in a transgender man. <i>Clinical Endocrinology</i> , 2020, 93, 355-357.	2.4	10
69	Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer. <i>Cancer Research</i> , 2020, 80, PD7-05-PD7-05.	0.9	10
70	Effects of Endocrine Therapy on Cognitive Function in Patients with Breast Cancer: A Comprehensive Review. <i>Cancers</i> , 2022, 14, 920.	3.7	10
71	Adjuvant endocrine therapy in women with oestrogen receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed?. <i>Clinical Endocrinology</i> , 2016, 85, 689-693.	2.4	9
72	Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. <i>Npj Breast Cancer</i> , 2021, 7, 111.	5.2	9

#	ARTICLE	IF	CITATIONS
73	Type 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic. <i>Cancers</i> , 2021, 13, 4972.	3.7	9
74	Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 63.	5.0	8
75	⁶⁴ Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial. <i>Pharmaceuticals</i> , 2022, 15, 772.	3.8	8
76	The influence of language spoken on colorectal cancer diagnosis and management. <i>ANZ Journal of Surgery</i> , 2006, 76, 671-672.	0.7	7
77	Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review. <i>Frontiers in Oncology</i> , 2021, 11, 701424.	2.8	7
78	The management of HER2-positive early breast cancer: Current and future therapies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-12.	1.1	7
79	Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones. <i>Cancers</i> , 2022, 14, 2292.	3.7	6
80	OPTIMIZING THE APPROACH TO PATIENTS WITH POTENTIALLY RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER. <i>ANZ Journal of Surgery</i> , 2007, 77, 941-947.	0.7	5
81	Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC). <i>Cancer Research</i> , 2022, 82, PD13-07-PD13-07.	0.9	5
82	Sensitizing HR-proficient cancers to PARP inhibitors. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1299272.	0.7	4
83	Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. <i>EBioMedicine</i> , 2018, 29, 166-176.	6.1	4
84	Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 3-11.	1.1	4
85	The International Academy of Cytology Yokohama System for Reporting Breast Fine Needle Aspiration Biopsy Cytopathology: Introduction and Overview. , 2020, , 1-9.		4
86	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2021, 13, 5527.	3.7	4
87	MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 777867.	2.8	4
88	Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 3-14.	1.1	3
89	Abstract 129: An integrated multi-omic cellular atlas of human breast cancers. <i>Cancer Research</i> , 2021, 81, 129-129.	0.9	3
90	Abstract 1788: The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition.. , 2013, , .		3

#	ARTICLE	IF	CITATIONS
91	Diagnostic value of 68 Ga ⁶⁷ DOTATATE PET-CT imaging for staging of ER + /PR + HER2 ⁺ breast cancer patients with metastatic disease: Comparison with conventional imaging with bone scan, diagnostic CT and 18 F ¹⁸ FDG PET-CT in a prospective pilot trial. Journal of Medical Imaging and Radiation Oncology, 2021, , .	1.8	3
92	A new sophistication for breast cancer PDXs. Nature Cancer, 2022, 3, 138-140.	13.2	3
93	Window of opportunity treatment in breast cancer. ANZ Journal of Surgery, 2020, 90, 34-40.	0.7	2
94	Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. Cancers, 2022, 14, 2404.	3.7	2
95	Diagnosing cancer: changing patterns of care. Internal Medicine Journal, 2007, 37, 124-126.	0.8	1
96	Attitudes of patients with metastatic cancer towards research biopsies. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 231-238.	1.1	1
97	Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2 ⁻ amplified metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 12-21.	1.1	1
98	Estrogen receptor positive breast cancer patient ⁻ derived xenograft models in translational research. Current Opinion in Endocrine and Metabolic Research, 2020, 15, 31-36.	1.4	1
99	Testosterone therapy considerations in oestrogen, progesterone and androgen receptor ⁻ positive breast cancer in a transgender man. , 2020, 93, 355.		1
100	Will preoperative trials change future clinical practice?. Clinical Investigation, 2011, 1, 59-73.	0.0	1
101	Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study. Cancer Research, 2020, 80, P5-14-05-P5-14-05.	0.9	1
102	Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing. Breast Cancer Research and Treatment, 2021, 191, 501.	2.5	1
103	Adjuvant Chemotherapy in Breast Cancer. , 2015, , 335-351.		0
104	OR05-06 The Androgen Receptor Is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer. Journal of the Endocrine Society, 2020, 4, .	0.2	0
105	Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases.. , 2013, , .		0
106	Abstract P3-05-14: Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer. , 2015, , .		0